These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 24681936)

  • 1. [Efficacy of chemotherapy combined with bortezomib for two cases of relapsed/refractory acute lymphoblastic leukemia].
    Keino D; Ohyama R; Ashikaga T; Morimoto M; Yamashita A; Kondoh K; Kinoshita A
    Rinsho Ketsueki; 2014 Mar; 55(3):327-33. PubMed ID: 24681936
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase I study of bortezomib combined with chemotherapy in children with relapsed childhood acute lymphoblastic leukemia (ALL): a report from the therapeutic advances in childhood leukemia (TACL) consortium.
    Messinger Y; Gaynon P; Raetz E; Hutchinson R; Dubois S; Glade-Bender J; Sposto R; van der Giessen J; Eckroth E; Bostrom BC
    Pediatr Blood Cancer; 2010 Aug; 55(2):254-9. PubMed ID: 20582937
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bortezomib with chemotherapy is highly active in advanced B-precursor acute lymphoblastic leukemia: Therapeutic Advances in Childhood Leukemia & Lymphoma (TACL) Study.
    Messinger YH; Gaynon PS; Sposto R; van der Giessen J; Eckroth E; Malvar J; Bostrom BC;
    Blood; 2012 Jul; 120(2):285-90. PubMed ID: 22653976
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The combination of bortezomib with chemotherapy to treat┬árelapsed/refractory acute lymphoblastic leukaemia of childhood.
    Bertaina A; Vinti L; Strocchio L; Gaspari S; Caruso R; Algeri M; Coletti V; Gurnari C; Romano M; Cefalo MG; Girardi K; Trevisan V; Bertaina V; Merli P; Locatelli F
    Br J Haematol; 2017 Feb; 176(4):629-636. PubMed ID: 28116786
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment of children with relapsed and refractory acute lymphoblastic leukemia with mitoxantrone, vincristine, pegaspargase, dexamethasone, and bortezomib.
    August KJ; Guest EM; Lewing K; Hays JA; Gamis AS
    Pediatr Blood Cancer; 2020 Mar; 67(3):e28062. PubMed ID: 31724803
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Salvage therapy with pegylated liposomal doxorubicin, bortezomib, cyclophosphamide, and dexamethasone in relapsed/refractory myeloma patients.
    Romano A; Chiarenza A; Conticello C; Cavalli M; Vetro C; Di Raimondo C; Cunsolo R; Palumbo GA; Di Raimondo F
    Eur J Haematol; 2014 Sep; 93(3):207-13. PubMed ID: 24673398
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A comparison of bortezomib, cyclophosphamide, and dexamethasone (Vel-CD) chemotherapy without and with thalidomide (Vel-CTD) for the treatment of relapsed or refractory multiple myeloma.
    Ahn JS; Yang DH; Jung SH; Park HC; Moon JH; Sohn SK; Bae SY; Kim YK; Kim HJ; Lee JJ;
    Ann Hematol; 2012 Jul; 91(7):1023-30. PubMed ID: 22314843
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A phase I window, dose escalating and safety trial of metformin in combination with induction chemotherapy in relapsed refractory acute lymphoblastic leukemia: Metformin with induction chemotherapy of vincristine, dexamethasone, PEG-asparaginase, and doxorubicin.
    Trucco M; Barredo JC; Goldberg J; Leclerc GM; Hale GA; Gill J; Setty B; Smith T; Lush R; Lee JK; Reed DR
    Pediatr Blood Cancer; 2018 Sep; 65(9):e27224. PubMed ID: 29856514
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bortezomib-containing therapy in Japanese children with relapsed acute lymphoblastic leukemia.
    Hasegawa D; Yoshimoto Y; Kimura S; Kumamoto T; Maeda N; Hara J; Kikuta A; Kada A; Kimura T; Iijima-Yamashita Y; Saito AM; Horibe K; Manabe A; Ogawa C
    Int J Hematol; 2019 Nov; 110(5):627-634. PubMed ID: 31401767
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A phase I clinical-pharmacodynamic study of the farnesyltransferase inhibitor tipifarnib in combination with the proteasome inhibitor bortezomib in advanced acute leukemias.
    Lancet JE; Duong VH; Winton EF; Stuart RK; Burton M; Zhang S; Cubitt C; Blaskovich MA; Wright JJ; Sebti S; Sullivan DM
    Clin Cancer Res; 2011 Mar; 17(5):1140-6. PubMed ID: 21233404
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bortezomib and dexamethasone as salvage therapy in patients with relapsed/refractory multiple myeloma: analysis of long-term clinical outcomes.
    Pantani L; Zamagni E; Zannetti BA; Pezzi A; Tacchetti P; Brioli A; Mancuso K; Perrone G; Rocchi S; Tosi P; Cavo M
    Ann Hematol; 2014 Jan; 93(1):123-8. PubMed ID: 23864035
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Low-dose oral etoposide-based induction regimen for children with acute lymphoblastic leukemia in first bone marrow relapse.
    Hijiya N; Gajjar A; Zhang Z; Sandlund JT; Ribeiro RC; Rubnitz JE; Jeha S; Liu W; Cheng C; Raimondi SC; Behm FG; Rivera GK; Relling MV; Pui CH
    Leukemia; 2004 Oct; 18(10):1581-6. PubMed ID: 15356657
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Bortezomib-Based Protocol Induces a High Rate of Complete Remission with Minor Toxicity in Adult Patients with Relapsed/Refractory Acute Lymphoblastic Leukemia.
    Nachmias B; Shaulov A; Gatt ME; Shapira M; Gural A
    Acta Haematol; 2018; 140(4):209-214. PubMed ID: 30343286
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase 1 trial of the proteasome inhibitor bortezomib and pegylated liposomal doxorubicin in patients with advanced hematologic malignancies.
    Orlowski RZ; Voorhees PM; Garcia RA; Hall MD; Kudrik FJ; Allred T; Johri AR; Jones PE; Ivanova A; Van Deventer HW; Gabriel DA; Shea TC; Mitchell BS; Adams J; Esseltine DL; Trehu EG; Green M; Lehman MJ; Natoli S; Collins JM; Lindley CM; Dees EC
    Blood; 2005 Apr; 105(8):3058-65. PubMed ID: 15626743
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bortezomib-contained chemotherapy and thalidomide combined with CHOP (Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone) play promising roles in plasmablastic lymphoma: a case report and literature review.
    Cao C; Liu T; Zhu H; Wang L; Kai S; Xiang B
    Clin Lymphoma Myeloma Leuk; 2014 Oct; 14(5):e145-50. PubMed ID: 25225082
    [No Abstract]   [Full Text] [Related]  

  • 16. Combination chemotherapy with bortezomib, cyclophosphamide and dexamethasone may be effective for plasma cell leukemia.
    Kim SJ; Kim J; Cho Y; Seo BK; Kim BS
    Jpn J Clin Oncol; 2007 May; 37(5):382-4. PubMed ID: 17538191
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bortezomib, Dexamethasone, Mitoxantrone, and Vinorelbine (BDMV): An Active Reinduction Regimen for Children With Relapsed Acute Lymphoblastic Leukemia and Asparaginase Intolerance.
    Yeo KK; Gaynon PS; Fu CH; Wayne AS; Sun W
    J Pediatr Hematol Oncol; 2016 Jul; 38(5):345-9. PubMed ID: 27352191
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment with bortezomib in a patient with heavily pretreated refractory T-cell lymphoblastic lymphoma.
    Mai W; Meng H; Jin J; Wang L
    Eur J Haematol; 2006 Nov; 77(5):445-7. PubMed ID: 16930138
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Bortezomib-based combination therapy for relapsed or refractory multiple myeloma].
    Yuan ZG; Hou J; Wang DX; Fu WJ; Chen YB; Xi H
    Zhonghua Nei Ke Za Zhi; 2008 Feb; 47(2):102-6. PubMed ID: 18683793
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combination therapy of recurrent prostate cancer with the proteasome inhibitor bortezomib plus hormone blockade.
    Kraft AS; Garrett-Mayer E; Wahlquist AE; Golshayan A; Chen CS; Butler W; Bearden J; Lilly M
    Cancer Biol Ther; 2011 Jul; 12(2):119-24. PubMed ID: 21532336
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.